iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
10.02
-0.01 (-0.10%)
At close: May 30, 2025, 4:00 PM
10.05
+0.03 (0.30%)
After-hours: May 30, 2025, 7:45 PM EDT
iTeos Therapeutics Revenue
iTeos Therapeutics had revenue of $35.00M in the twelve months ending March 31, 2025. In the year 2024, iTeos Therapeutics had annual revenue of $35.00M with 177.89% growth.
Revenue (ttm)
$35.00M
Revenue Growth
+177.89%
P/S Ratio
12.12
Revenue / Employee
$202,312
Employees
173
Market Cap
383.50M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ITOS News
- 3 days ago - iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewsWire
- 18 days ago - iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 4 weeks ago - iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire
- 3 months ago - iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless - Seeking Alpha
- 5 months ago - iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 - Seeking Alpha
- 6 months ago - iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - GlobeNewsWire